JP2024542635A5 - - Google Patents

Info

Publication number
JP2024542635A5
JP2024542635A5 JP2024532179A JP2024532179A JP2024542635A5 JP 2024542635 A5 JP2024542635 A5 JP 2024542635A5 JP 2024532179 A JP2024532179 A JP 2024532179A JP 2024532179 A JP2024532179 A JP 2024532179A JP 2024542635 A5 JP2024542635 A5 JP 2024542635A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
fusion
hmpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542635A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080555 external-priority patent/WO2023102373A1/en
Publication of JP2024542635A publication Critical patent/JP2024542635A/ja
Publication of JP2024542635A5 publication Critical patent/JP2024542635A5/ja
Pending legal-status Critical Current

Links

JP2024532179A 2021-11-30 2022-11-29 ヒトメタニューモウイルスワクチン Pending JP2024542635A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284405P 2021-11-30 2021-11-30
US63/284,405 2021-11-30
PCT/US2022/080555 WO2023102373A1 (en) 2021-11-30 2022-11-29 Human metapneumovirus vaccines

Publications (2)

Publication Number Publication Date
JP2024542635A JP2024542635A (ja) 2024-11-15
JP2024542635A5 true JP2024542635A5 (https=) 2025-12-08

Family

ID=84602059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532179A Pending JP2024542635A (ja) 2021-11-30 2022-11-29 ヒトメタニューモウイルスワクチン

Country Status (13)

Country Link
US (1) US20230310571A1 (https=)
EP (1) EP4440608A1 (https=)
JP (1) JP2024542635A (https=)
KR (1) KR20240118798A (https=)
CN (1) CN118338911A (https=)
AR (1) AR127808A1 (https=)
AU (1) AU2022399571A1 (https=)
CA (1) CA3239417A1 (https=)
CO (1) CO2024007274A2 (https=)
IL (1) IL312997A (https=)
MX (1) MX2024006240A (https=)
TW (1) TW202340227A (https=)
WO (1) WO2023102373A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2025119162A1 (zh) * 2023-12-04 2025-06-12 深圳深信生物科技有限公司 偏肺病毒(mpv)疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2025250938A2 (en) * 2024-05-31 2025-12-04 Modernatx, Inc. Respiratory syncytial virus and metapneumovirus vaccines
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026027730A1 (en) * 2024-07-31 2026-02-05 Sanofi Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
CN119978144B (zh) * 2025-02-14 2025-10-17 嘉译生物医药(杭州)有限公司 一种hMPV病毒融合蛋白F变体、mRNA疫苗及其应用
CN121221752A (zh) * 2025-02-14 2025-12-30 北京悦康科创医药科技股份有限公司 一种膜融合抑制多肽在抗副黏病毒科病毒感染中的应用
CN119971017B (zh) * 2025-04-16 2025-08-05 北京华诺泰生物医药科技有限公司 一种hmpv疫苗组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5684042A (en) 1997-01-10 1997-11-04 Medlogic Global Corporation Cyanoacrylate compositions comprising an antimicrobial agent
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
EP2445527A2 (en) * 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP2519636B8 (en) 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
CA3028175C (en) 2009-12-28 2022-05-24 Sanofi Vaccine Technologies, S.A.S. Methods of producing heterologous viral neuraminidase proteins in microalgae
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
BR112015022505A2 (pt) 2013-03-14 2017-10-24 Shire Human Genetic Therapies avaliação quantitativa para eficiência do cap de rna mensageiro
EP3388834B1 (en) 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
KR102354389B1 (ko) 2013-08-21 2022-01-20 큐어백 아게 Rna―암호화된 단백질의 발현을 증가시키는 방법
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
CN111304231A (zh) 2013-12-30 2020-06-19 库瑞瓦格股份公司 人工核酸分子
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
PT4023755T (pt) 2014-12-12 2023-07-05 CureVac SE Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
CA3043033A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
CA3146675A1 (en) 2019-07-23 2021-01-28 Translate Bio, Inc. Stable compositions of mrna-loaded lipid nanoparticles and processes of making

Similar Documents

Publication Publication Date Title
JP2024542635A5 (https=)
JP2024542085A5 (https=)
CN103747797B (zh) 脂质体制剂
JP2026040566A (ja) SARS-CoV-2ワクチン
ES2337901T3 (es) Vacuna de subunidad contra infeccion por el virus respiratorio sincicial.
JP2023522249A5 (https=)
EP3638284B1 (en) Cyclic peptides for protection against respiratory syncytial virus
US20230399364A1 (en) Immunogenic Coronavirus Fusion Proteins and Related Methods
WO2018200613A1 (en) Hsv antigenic peptides and hsv protein vaccines
JP2024544054A5 (https=)
CN113769080B (zh) 多肽免疫偶联物及其应用
CN118043451A (zh) 疫苗抗原
JP2026506447A (ja) 呼吸器合胞体ウイルスmRNAワクチン
CN112574298B (zh) 一种抗西尼罗河病毒的人源中和性抗体
JP2025529906A (ja) コロナウイルスに対するワクチン
Wilks et al. Peptide Cross-Linking Using Tyrosine Residues Facilitated by an Exogenous Nickel–Histidine Complex: A Facile Approach for Enhancing Vaccine-Specific Immunogenicity
CN120202020A (zh) 工程化水痘带状疱疹病毒带状疱疹mRNA疫苗
RU2024117908A (ru) Вакцины против метапневмовируса человека
WO2023060483A1 (zh) 多肽-rbd免疫偶联物及其用途
CN120586030A (zh) 一种多价克里米亚刚果出血热mRNA疫苗及其制备方法与应用
RU2025134895A (ru) Комбинированные вакцины на основе мрнк респираторных патогенов
WO2007107597A2 (en) Immunogenic construct and a method for the prophylactic or therapeutic treatment of aids
WO2024130061A1 (en) Immunogenic ebolavirus fusion proteins and related methods
WO2024059149A2 (en) Immunogenic coronavirus fusion proteins and related methods
JP2023520038A (ja) ウイルス様粒子を作製するためのベクターおよびその使用